Applied DNA Announces Upsized Public Offering of $12 Million at a Premium Price to Market Under Nasdaq Rules

Stony Brook, NY, August 04, 2022,business wire) — Applied DNA Sciences, Inc., (NASDAQ: APDN) (“The Company” or “Applied DNA”), a leader in polymerase chain reaction (“PCR”)-based technologies, today announced the pricing of a public offering . Series B warrants to buy 3,000,000 shares of your common stock with Series A warrants, and 3,000,000 shares of your common stock on a joint offering, along with 3,000,000 shares of your common stock (or the common stock equivalent thereof) Under Nasdaq rules $4.00 per share (or common stock equivalent) at a premium price to the market and the price to the public of related warrants. The Series A warrant will have an exercise price of $4.00 per share, be exercisable immediately upon issue, and expire five years after the date of issue. Series B warrants will have an exercise price of $4.00 per share, can be exercised immediately upon issue, and will expire 13 months after the date of issue. The Offering is expected to close on or around August 8, 2022, subject to the satisfaction of customary closing conditions.

HC Wainwright & Company is acting as the exclusive placement agent for the offering.

The Company expects gross income from the Offering to be $12 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for the development of the Company’s therapeutic DNA production and MDX testing services, as well as for general corporate purposes, which include research and development expenses, capital expenditures, working capital and general and administrative expenses. can be. , and potential acquisitions or investments in businesses, products and technologies that complement our business, although the Company has no current commitment or agreement to make any such acquisitions or investments.

The securities described above are being offered in accordance with a registration statement on Form S-1 (File No. 333-266223) previously filed with the Securities and Exchange Commission (SEC), effective August 4, 2022 And an additional registration statement was filed. As per Rule 462(b) which automatically came into force on 4th August, 2022. The offer is being made only through a prospectus, which is part of the effective registration details. When available, electronic copies of the final prospectus can be obtained for free on the SEC’s website: and HC Wainwright & Company, LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022 by phone (212) 856-5711 or by e-mail at

This press release does not constitute a solicitation of an offer to sell or purchase any of the securities described herein, nor shall there be any sale of these securities in any State or other jurisdiction in which such offer, solicitation or sale shall take place in any such State or To be unlawful prior to registration or qualification under the securities laws of the other jurisdiction.

About applied DNA science

Applied DNA Sciences is a biotechnology company developing technologies for the production and detection of deoxyribonucleic acid (“DNA”). Using PCR to enable both the production and detection of DNA, we operate in three primary commercial markets: (i) the manufacture of DNA for use in nucleic acid-based therapeutics; (ii) DNA detection in molecular diagnostics testing services; and (iii) manufacturing and tracing DNA for industrial supply chain security services.

meeting for more information. What should I follow Twitter And linkedin, join our mailing list,

The company’s common stock is listed on the NASDAQ under the ticker symbol ‘APDN’, and its publicly traded warrants are listed on the OTC under the ticker symbol ‘APPDW’.

forward-looking statements

The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond Applied DNA’s control. Forward-looking statements include statements relating to the Offering, including the completion of the Offering, the satisfaction of customary closing conditions relating to the Offering, expected proceeds from the Offering and the intended use of the net proceeds, timing of closing. Warrant offer and possible exercise. Actual results may differ materially from those projected due to its history of actual losses, limited financial resources, limited market acceptance, the possibility that Applied DNA’s testing services may become obsolete or lose their usefulness, and an unknown amount of revenue and Benefit from Applied DNA’s testing services. In addition, uncertainties inherent in research and development, future data, and analysis of whether any of Applied DNA’s current or future clinical candidates will proceed in the research and/or validation process or the FDA, equivalent foreign authorization , will receive approval or approval. regulatory agencies and/or the New York State Department of Health (“NYSDOH”), and whether and when, if at all, they will receive final authorization, approval or approval from FDA, equivalent foreign regulatory agencies and/or NYSDOH, FDA, equivalent foreign The undisclosed result of any application or request to regulatory agencies and/or the NYSDOH, disruption of the supply of raw materials and supplies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our annual. Report on Form 10-K filed on December 9, 2021, its quarterly report on Form 10-Q filed on February 10, 2022 and May 12, 2022, and other reports that we file with the SEC, which are here are available, Applied DNA undertakes no obligation to publicly update any forward-looking statements after this date to reflect new information, events or circumstances or the occurrence of unforeseen events, unless otherwise permitted by law. not necessary.

View the source version at


Investor Relations Contact: Sanjay M. Jaldi, 917-733-5573,
Twitter: @APDN

Be the first to comment

Leave a Reply

Your email address will not be published.